Does the use of mild behavioral impairment (MBI) criteria optimize the detection of Alzheimer's disease in patients with mild cognitive impairment?
Mild behavioral impairment criteria can improve the identification of patients with mild cognitive impairment for Alzheimer's disease trials and clinical care.
These findings support a biological basis for NPS that meet MBI criteria, the continued inclusion of MBI in NIA-AA ATN clinical staging, and the utility of MBI criteria to improve identification of patients for enrollment in disease-modifying drug trials or for clinical care.
Ismail et al. (Sat,) studied this question.